Rate of differentiation syndrome in patients based on timing of initial all-trans retinoic acid administration

All-trans-retinoic acid (ATRA) is the standard of care for the management of acute promyelocytic leukemia (APL), but can be associated with differentiation syndrome (DS). Over a seven-year period, we sought to determine the impact of ATRA initiation time on the development of DS. ATRA administration...

Descripción completa

Detalles Bibliográficos
Autores principales: Nauffal, Mary, Werner, Lillian, Ni, Jian, Stone, Richard M., DeAngelo, Daniel J., McDonnell, Anne M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6904816/
https://www.ncbi.nlm.nih.gov/pubmed/31867205
http://dx.doi.org/10.1016/j.lrr.2019.100189
_version_ 1783478060421480448
author Nauffal, Mary
Werner, Lillian
Ni, Jian
Stone, Richard M.
DeAngelo, Daniel J.
McDonnell, Anne M.
author_facet Nauffal, Mary
Werner, Lillian
Ni, Jian
Stone, Richard M.
DeAngelo, Daniel J.
McDonnell, Anne M.
author_sort Nauffal, Mary
collection PubMed
description All-trans-retinoic acid (ATRA) is the standard of care for the management of acute promyelocytic leukemia (APL), but can be associated with differentiation syndrome (DS). Over a seven-year period, we sought to determine the impact of ATRA initiation time on the development of DS. ATRA administration time had no impact on DS occurrence (p = =0.13), APL risk (p = =0.28) or regimen received (p = =0.1). Patients with higher mean body mass index (BMI) were more likely to develop moderate or severe DS (p = =0.02). Early treatment of APL is essential and maybe strongly considered in patients with elevated BMI.
format Online
Article
Text
id pubmed-6904816
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-69048162019-12-20 Rate of differentiation syndrome in patients based on timing of initial all-trans retinoic acid administration Nauffal, Mary Werner, Lillian Ni, Jian Stone, Richard M. DeAngelo, Daniel J. McDonnell, Anne M. Leuk Res Rep Article All-trans-retinoic acid (ATRA) is the standard of care for the management of acute promyelocytic leukemia (APL), but can be associated with differentiation syndrome (DS). Over a seven-year period, we sought to determine the impact of ATRA initiation time on the development of DS. ATRA administration time had no impact on DS occurrence (p = =0.13), APL risk (p = =0.28) or regimen received (p = =0.1). Patients with higher mean body mass index (BMI) were more likely to develop moderate or severe DS (p = =0.02). Early treatment of APL is essential and maybe strongly considered in patients with elevated BMI. Elsevier 2019-11-27 /pmc/articles/PMC6904816/ /pubmed/31867205 http://dx.doi.org/10.1016/j.lrr.2019.100189 Text en © 2019 The Authors. Published by Elsevier Ltd. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Nauffal, Mary
Werner, Lillian
Ni, Jian
Stone, Richard M.
DeAngelo, Daniel J.
McDonnell, Anne M.
Rate of differentiation syndrome in patients based on timing of initial all-trans retinoic acid administration
title Rate of differentiation syndrome in patients based on timing of initial all-trans retinoic acid administration
title_full Rate of differentiation syndrome in patients based on timing of initial all-trans retinoic acid administration
title_fullStr Rate of differentiation syndrome in patients based on timing of initial all-trans retinoic acid administration
title_full_unstemmed Rate of differentiation syndrome in patients based on timing of initial all-trans retinoic acid administration
title_short Rate of differentiation syndrome in patients based on timing of initial all-trans retinoic acid administration
title_sort rate of differentiation syndrome in patients based on timing of initial all-trans retinoic acid administration
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6904816/
https://www.ncbi.nlm.nih.gov/pubmed/31867205
http://dx.doi.org/10.1016/j.lrr.2019.100189
work_keys_str_mv AT nauffalmary rateofdifferentiationsyndromeinpatientsbasedontimingofinitialalltransretinoicacidadministration
AT wernerlillian rateofdifferentiationsyndromeinpatientsbasedontimingofinitialalltransretinoicacidadministration
AT nijian rateofdifferentiationsyndromeinpatientsbasedontimingofinitialalltransretinoicacidadministration
AT stonerichardm rateofdifferentiationsyndromeinpatientsbasedontimingofinitialalltransretinoicacidadministration
AT deangelodanielj rateofdifferentiationsyndromeinpatientsbasedontimingofinitialalltransretinoicacidadministration
AT mcdonnellannem rateofdifferentiationsyndromeinpatientsbasedontimingofinitialalltransretinoicacidadministration

Ejemplares similares